- Report
- February 2024
- 50 Pages
Global
From €2291EUR$2,400USD£1,919GBP
- Report
- June 2022
- 1500 Pages
Global
From €3722EUR$3,900USD£3,119GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €8589EUR$9,000USD£7,197GBP
- Report
- February 2022
- 360 Pages
United States
From €3436EUR$3,600USD£2,879GBP
- Report
- December 2021
- 120 Pages
Global
From €3149EUR$3,300USD£2,639GBP
- Report
- December 2018
- 288 Pages
Global
From €1312EUR$1,375USD£1,099GBP
€2625EUR$2,750USD£2,199GBP
- Report
- October 2023
- 85 Pages
United States
From €4629EUR$4,850USD£3,878GBP
- Report
- December 2022
- 153 Pages
Global
From €2505EUR$2,625USD£2,099GBP
€5010EUR$5,250USD£4,198GBP
- Report
- February 2022
- 172 Pages
Global
From €2854EUR$2,990USD£2,391GBP
- Report
- September 2023
- 98 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- April 2022
- 233 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- October 2023
- 189 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- June 2023
- 241 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- April 2023
- 350 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Report
- October 2022
- 300 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- February 2024
- 245 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2386EUR$2,500USD£1,999GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more